logo-loader
viewAdmedus Ltd

Admedus appoints medtech expert Michael Oswell as vice president, development

Oswell's background in product development is expected to benefit Admedus' portfolio of development projects.

two people shaking hands
Oswell's most recent role was as senior program manager at Medtronic

Admedus Ltd (ASX:AHZ) has appointed Michael Oswell to the newly created role of vice president, development.

Based in the U.S., Oswell will be responsible for accelerating the company’s product pipeline, including its portfolio of 3D surgical solutions and the Transcatheter Aortic Valve Replacement (TAVR) device project.

READ: Admedus takes significant step forward in developing unique heart valve device

Oswell brings extensive experience in the medical technology industry, including senior leadership roles with Guidant Corp. (Boston Scientific) and Medtronic Pty Ltd.

His most recent role was as senior program manager at Medtronic (cardiac rhythm and heart failure operations).

Progressing a range of new products in the development pipeline

Admedus chief executive officer Wayne Paterson said: “Michael has a strong track record as a results-driven leader in the medtech environment.

“He will be an excellent addition to the Admedus leadership team and his technical skill and experience will be an enormous advantage as we look to progress our range of new products in our development pipeline.

“His background in product development for some of the leading companies in the medtech industry will bring invaluable new perspective to our portfolio of development projects.”

Admedus recently submitted several new provisional patent applications in the U.S. for further development of its novel TAVR device.

TAVR is where a valve is placed into the heart via a catheter (usually inserted through the leg) to replace the aortic valve, eliminating the need for open-heart surgery.

READ: Admedus enters into letter of intent to arrange alternative funding for immunotherapies division

Quick facts: Admedus Ltd

Price: 0.088 AUD

ASX:AHZ
Market: ASX
Market Cap: $51.99 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Admedus Ltd named herein, including the promotion by the Company of Admedus Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Admedus CEO in New York to update on recent key milestones

Admedus Ltd (ASX:AHZ) CEO Wayne Paterson visited the Proactive Investors New York studio to update on key milestones the company has achieved in the past few months, including receiving European approval on two of its products.

on 03/17/2019

2 min read